Bruker Daltonics Introduces Next-Generation Horizontal Top-of-the-Line MALDI-TOF/TOF Mass Spectrometer at IMSC.

PRAGUE, Czech Republic -- Next-Generation ultraflex III Offers Unique Smartbeam Technology, Further Boosts Sensitivity and Triples Acquisition Speed for Most Advanced LC-MALDI Workflow

At the 17th International Mass Spectrometry Conference IMSC, Bruker Daltonics today announces its next-generation horizontal top-of-the-line ultraflex(R) III smartbeam(TM) MALDI-TOF/TOF mass spectrometer. The new ultraflex III combines various innovative features and further pushes the TOF/TOF performance envelope for applications like LC-MALDI and MALDI molecular imaging, where highest sensitivity and speed are required.

An even further improved smartbeam laser with computer-controlled settings of the laser focus size from 10 um to 80 um makes the new ultraflex III an ideal choice for MALDI molecular imaging. Absorbing tissue areas can now be scanned with a very small laser focus and adjustable repetition rates from 1 Hz to 200 Hz, providing maximum sensitivity.

The ultraflex III boosts sensitivity even further and increases acquisition speed by a factor of three for LC-MALDI workflows, in comparison to the previous ultraflex II system. The all-purpose WARP-LC(TM) workflow software supports intelligent, result-dependent LC-MALDI acquisition, protein sequence validation, PTM screening and accurate quantitative proteomics for all label chemistries, to ensure outstanding top-of-the-line ultraflex III TOF/TOF performance.

"Its further sensitivity and speed performance enhancements make the ultraflex III the cutting-edge system in virtually all MALDI-TOF/TOF applications. Our unique smartbeam technology, in combination with the new variable focus size, makes the ultraflex III most versatile not only for MALDI imaging but for a broad range of large molecule analyses," stated Bruker Daltonics Vice President Dr. Ian Sanders. "Our extensive, fully-integrated MALDI-TOF product portfolio, including our brand-new autoflex III smartbeam and ultraflex III smartbeam TOF/TOF instruments, further establishes Bruker Daltonics' leadership position in expression proteomics and clinical proteomics."

For further information on IMSC, please visit www.imsc2006.org

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of nuclear, biological and chemical (NBC) detection products for homeland security. Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.